[The use of Cinacalcet in chronic kidney disease: a case report].

Abstract

Secondary Hyperparathyroidism is an important concurrent cause of cardiovascular and osteo-articular events, as well as, high morbidity and mortality for patients suffering from chronic kidney disease in conservative therapy and dialysis. The usual therapies, such as the vitamin D active metabolites and the phosphate binders did not always demonstrate effective in SHP control. New drugs, such as the calcimimetics, are available, resulting beneficial in highly reducing PTH levels. The only calcimimetic drug clinically used is cinacalcet, whose use is planned only in patients undergoing dialysis (peritoneal and extracorporeal). We describe the clinical case of a caucasian woman of 82 yrs old, with chronic kidney disease and secondary hyperparathyroidism resistant to usual therapies, in conservative treatment, which is prescribed cinacalcet (off-label). At first we found a worsening of the indices of renal function secondary to the effects of the drug on the hydrosaline balance. Increasing the hydrosaline intake we have seen the reduction and the subsequent stability of exams. Cinacalcet was effective in controlling the levels of parathyroid hormone and has contributed significantly to the achievement of optimal calcium-phosphorus balance. In view of these data, there is no doubt in taking in consideration the use of this drug also in the earliest stages of IRC.

• Authors: Roberta Russo, Gennaro Argentino, Immacolata Daniela Maresca, Giuseppina Sannino, Andrea Memoli, Bruno Memoli
• Journal: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia (G Ital Nefrol) 2015 Jul-Aug Vol. 32 Issue 4 ISSN: 1724-5990 [Electronic] Italy
• Vernacular Title: Utilizzo del calcio-mimetico in terapia conservativa: un caso clinico.
• PMID: 26252263 (Publication Type: Case Reports, Journal Article)

Chemical References

• Calcimimetic Agents
• Cinacalcet

Topics

• Aged, 80 and over
• Calcimimetic Agents (therapeutic use)
• Cinacalcet (therapeutic use)
• Female
• Humans
• Hyperparathyroidism, Secondary (drug therapy, etiology)
• Renal Insufficiency, Chronic (complications)